European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
MRNA has more than doubled off its 52-week low of $22.28.
Summary
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for Moderna's mCOMBRIAX, a combination vaccine targeting both influenza and COVID-19. This marks a significant regulatory milestone, as mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive such a recommendation. This positive development follows Moderna's recent 10-K filing (February 20), which highlighted a significant revenue decline and a pipeline setback with its CMV vaccine. A final approval by the European Commission would introduce a new, potentially substantial revenue stream for Moderna in the EU, diversifying its product portfolio and addressing a large market for combined respiratory virus protection. Investors should now watch for the European Commission's final decision on marketing authorization and subsequent national regulatory and access procedures.
At the time of this announcement, MRNA was trading at $51.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.4B. The 52-week trading range was $22.28 to $55.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Acceswire.